Case Reports
Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis
A. Ichihara1, M. Jinnin2, H. Ihn3
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. asa812ichi@yahoo.co.jp
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
CER10014
2017 Vol.35, N°4 ,Suppl.106
PI 0208, PF 0210
Case Reports
Free to view
(click on article PDF icon to read the article)
PMID: 28422002 [PubMed]
Received: 12/10/2016
Accepted : 23/01/2017
In Press: 19/04/2017
Published: 12/10/2017
Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by fibrosis, inflammation and vasculopathy in the skin and internal organs. Recently, several articles described that Th17 cells, IL-23 and IL-17 levels were significantly elevated in the peripheral blood or fibrotic sites of SSc. We report a case of SSc and psoriasis administered ustekinumab, IL-12/IL-23 inhibitor. In this case, the skin tightening was successfully improved and ustekinumab was more effective, even though oral prednisolone (9-12 mg/day) had some effect on skin tightening and arthralgia. We consider that inhibition of Th17 cytokines may lead to therapeutic efficacy against SSc. Ustekinumab has the potential for a treatment option of SSc.
